Shenogen is a new drug discovery and development venture focused on the discovery and development of small molecule and biologic drugs targeted at the novel Estrogen Receptor (ER) variant we have recently discovered and characterized.
Estrogen signaling is involved in a number of diseases with big market indications such as breast cancer, prostate cancer and osteoporosis.  By leveraging our unique combination of expertise on traditional Chinese herbal formulations with long history of human usage and our proprietary receptor-based bioassays, we have screened and identified a number of naturally derived bioactive chemical compounds specifically targeting the novel ER receptor. Based on the chemical structures of these lead compounds, we are developing a pipeline of drug candidates targeting estrogen-related disease indications.&......